Peptron, Inc. (087010.KQ)
KRW 98300.0
(-1.99%)
KRW 98300.0
(-1.99%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.34 Billion KRW | -42.52% |
| 2022 | 5.81 Billion KRW | -12.24% |
| 2021 | 6.62 Billion KRW | 112.28% |
| 2020 | 3.12 Billion KRW | 73.26% |
| 2019 | 1.8 Billion KRW | -53.36% |
| 2018 | 3.86 Billion KRW | 20.1% |
| 2017 | 3.21 Billion KRW | 2.7% |
| 2016 | 3.13 Billion KRW | 11.32% |
| 2015 | 2.81 Billion KRW | 13.24% |
| 2014 | 2.48 Billion KRW | -19.98% |
| 2013 | 3.1 Billion KRW | 0.09% |
| 2012 | 3.1 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 541.96 Million KRW | 13.56% |
| 2024 Q1 | 477.26 Million KRW | -40.32% |
| 2023 Q4 | 799.67 Million KRW | 17.0% |
| 2023 Q1 | 1.16 Billion KRW | 46.67% |
| 2023 Q3 | 683.46 Million KRW | -1.71% |
| 2023 Q2 | 695.35 Million KRW | -40.23% |
| 2023 FY | 3.34 Billion KRW | -42.52% |
| 2022 Q4 | 793.23 Million KRW | -35.38% |
| 2022 Q3 | 1.22 Billion KRW | 21.55% |
| 2022 Q2 | 1 Billion KRW | -63.72% |
| 2022 Q1 | 2.78 Billion KRW | 252.31% |
| 2022 FY | 5.81 Billion KRW | -12.24% |
| 2021 Q3 | 830.63 Million KRW | -80.2% |
| 2021 Q1 | 809.62 Million KRW | -1.45% |
| 2021 FY | 6.62 Billion KRW | 112.28% |
| 2021 Q2 | 4.19 Billion KRW | 418.05% |
| 2021 Q4 | 790.02 Million KRW | -4.89% |
| 2020 Q1 | 491.06 Million KRW | 10.5% |
| 2020 FY | 3.12 Billion KRW | 73.26% |
| 2020 Q4 | 821.52 Million KRW | -10.96% |
| 2020 Q3 | 922.65 Million KRW | 4.2% |
| 2020 Q2 | 885.44 Million KRW | 80.31% |
| 2019 Q3 | 393.86 Million KRW | 11.44% |
| 2019 Q2 | 353.42 Million KRW | -42.01% |
| 2019 FY | 1.8 Billion KRW | -53.36% |
| 2019 Q1 | 609.41 Million KRW | -36.66% |
| 2019 Q4 | 444.41 Million KRW | 12.83% |
| 2018 Q1 | 1.21 Billion KRW | -17.98% |
| 2018 Q3 | 881.12 Million KRW | 9.87% |
| 2018 FY | 3.86 Billion KRW | 20.1% |
| 2018 Q4 | 962.08 Million KRW | 9.19% |
| 2018 Q2 | 801.94 Million KRW | -34.08% |
| 2017 Q3 | 640.2 Million KRW | 11.27% |
| 2017 Q2 | 575.33 Million KRW | 11.38% |
| 2017 Q1 | 516.53 Million KRW | -39.58% |
| 2017 FY | 3.21 Billion KRW | 2.7% |
| 2017 Q4 | 1.48 Billion KRW | 131.7% |
| 2016 Q3 | 813.93 Million KRW | 6.37% |
| 2016 Q1 | 696.65 Million KRW | 6.5% |
| 2016 FY | 3.13 Billion KRW | 11.32% |
| 2016 Q2 | 765.22 Million KRW | 9.84% |
| 2016 Q4 | 854.88 Million KRW | 5.03% |
| 2015 Q3 | 912.19 Million KRW | 112.88% |
| 2015 FY | 2.81 Billion KRW | 13.24% |
| 2015 Q4 | 654.12 Million KRW | -28.29% |
| 2015 Q2 | 428.49 Million KRW | -47.59% |
| 2015 Q1 | 817.56 Million KRW | 0.0% |
| 2014 FY | 2.48 Billion KRW | -19.98% |
| 2014 Q2 | 737.16 Million KRW | 72.63% |
| 2014 Q1 | 427.03 Million KRW | 0.0% |
| 2014 Q3 | 906.22 Million KRW | 22.93% |
| 2013 FY | 3.1 Billion KRW | 0.09% |
| 2012 FY | 3.1 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Co., Ltd. | 42.9 Billion KRW | 92.21% |
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | 65.136% |
| BINEX Co., Ltd. | 154.82 Billion KRW | 97.841% |
| Bioneer Corporation | 263.23 Billion KRW | 98.73% |
| Anterogen.Co.,Ltd. | 6.5 Billion KRW | 48.588% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | 95.131% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | 31.5% |
| Helixmith Co., Ltd | 4.2 Billion KRW | 20.462% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 99.65% |
| Medy-Tox Inc. | 221.12 Billion KRW | 98.489% |
| Amicogen, Inc. | 159.9 Billion KRW | 97.91% |
| Genexine, Inc. | 4.42 Billion KRW | 24.505% |
| HLB Therapeutics Co.,Ltd. | 53.74 Billion KRW | 93.782% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | 90.213% |
| ALTEOGEN Inc. | 96.52 Billion KRW | 96.538% |
| PharmaResearch Co., Ltd. | 261.01 Billion KRW | 98.72% |
| SillaJen, Inc. | 3.93 Billion KRW | 15.171% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | 94.308% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | 80.416% |
| Genomictree Inc. | 3.41 Billion KRW | 2.227% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | 82.107% |
| EASY BIO,Inc. | 165.38 Billion KRW | 97.979% |
| GI Innovation, Inc. | 5.31 Billion KRW | 37.169% |